Susan Okie, MD has written a Perspective article in the 'New England Journal of Medicine' relating to a May ruling by the DC Circuit, US Court of Appeals. I agree strongly with the decision of one of the justices:
"The prerogative asserted by the FDA — to prevent a terminally ill patient from using potentially life-saving medication to which those in Phase II clinical trials have access...impinges upon an individual liberty deeply rooted in our Nation's history and tradition of self-preservation."
-Judge Judith Rogers
NEJM Interview on the subject.
In a related story, a study has been released showing the potent and imediate efficacy of the popular "street drug" ketamine as an anti-depressant. Currently, a severely depressed and potentially suicidal person who procures and uses ketamine could face years of imprisonment for using this "controlled substance."